MedTrace Logo

Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry

NCT05081336 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2021-10-25

No results posted yet for this study

Summary

Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS.

Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.

Conditions

  • Acute Coronary Syndrome
  • Dyslipidemias

Interventions

DRUG

Statin

Statin +/- ezetimib +/- Alirocumab

Sponsors & Collaborators

  • University Clinical Centre of Republic of Srpska

    lead OTHER

Principal Investigators

  • Bojan M Stanetic, MD, PhD · University Clinical Centre of the Republic of Srpska

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-01-31
Completion
2023-03-31

Countries

  • Bosnia and Herzegovina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05081336 on ClinicalTrials.gov